Document Detail


Complications following temporary occlusion of the nasolacrimal duct with tissue adhesive (Histoacryl)
MedLine Citation:
PMID:  3494156     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This paper presents 4 cases in which the punctum had been temporarily occluded with tissue adhesive, still showing toxic tissue reaction years later. Abscess, dacryocystitis, dacryocystitis with dacryolithiasis, dacryocellulitis and polyposis were found. In the light of these findings and the relevant literature-especially with regard to late injuries-it is not advisable to use tissue adhesive, at least not for the purpose of punctal occlusion.
Authors:
U Köhler
Publication Detail:
Type:  Case Reports; English Abstract; Journal Article    
Journal Detail:
Title:  Klinische Monatsblätter für Augenheilkunde     Volume:  189     ISSN:  0023-2165     ISO Abbreviation:  Klin Monbl Augenheilkd     Publication Date:  1986 Dec 
Date Detail:
Created Date:  1987-05-01     Completed Date:  1987-05-01     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0014133     Medline TA:  Klin Monbl Augenheilkd     Country:  GERMANY, WEST    
Other Details:
Languages:  ger     Pagination:  486-90     Citation Subset:  IM    
Vernacular Title:
Komplikationen nach vorübergehendem Tränennasenwegsverschluss mit Gewebekleber (Histoacryl).
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Enbucrilate / adverse effects*,  therapeutic use
Female
Herpes Zoster Ophthalmicus / therapy
Humans
Keratitis, Dendritic / therapy
Lacrimal Apparatus / drug effects*
Middle Aged
Nasolacrimal Duct / drug effects*
Retinal Detachment / therapy
Sjogren's Syndrome / therapy
Chemical
Reg. No./Substance:
6606-65-1/Enbucrilate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  T-lymphocyte subsets in primary lung cancer.
Next Document:  Evidence for the involvement of dopamine agonists and antagonists in duodenal ulcer disease.